Pluribus Labs’s Edwards Lifesciences EW Stock Holding History

Pluribus Labs’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-2,817	Closed	-$365K	–	116
2021 Q4	$365K	Buy	+2,817	New	+$329K	0.38%	95

Other funds holding EW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pluribus Labs's EW Position: Q1 2022 in Review

Pluribus Labs sold out of Edwards Lifesciences (EW) in Q1 2022, closing a stake of 2,817 shares — an estimated $365K sold.

Pluribus Labs first reported a position in EW in Q4 2021 and held it in 1 quarter. The position peaked at $365K in Q4 2021. 1,314 funds tracked by Wall St. Rank hold EW as of Q1 2022.

Pluribus Labs reported no remaining Edwards Lifesciences position as of Q1 2022 after selling out during the quarter.
Pluribus Labs sold 2,817 Edwards Lifesciences shares in Q1 2022, an estimated $365K.
Pluribus Labs first reported a position in Edwards Lifesciences in Q4 2021 and held it in 1 quarter.
Pluribus Labs's Edwards Lifesciences position peaked at $365K in Q4 2021.
1,314 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2022.

Based on Pluribus Labs's 13F filing for Q1 2022, filed 16 May 2022.